Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West Virginia University
• Treatments: Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Stage II - III Non Small Cell Lung Cancer

Exclusion Criteria:

• Primary tumor directly invading into any mediastinal structures, such as the heart, major blood vessels, esophagus, trachea, and the proximal bronchial tree.

• Prior chemotherapy for NSCLC

• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.

• Severe, active co-morbidity

• Pregnancy or women of childbearing potential

• Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin

• Uncontrolled neuropathy ≥ grade 2.